(Q34369646)

1 August 2017

title

Pimavanserin for the treatment of Parkinson's disease psychosis. (English)

1 reference

1 August 2017

1 reference

1 reference

ChEBI release 2020-05-28

1 reference

1

Joseph H Friedman

1 reference

1 August 2017

language of work or name

English

0 references

publication date

1 October 2013

1 reference

Expert Opinion on Pharmacotherapy

1 August 2017

published in

1 reference

1 August 2017

volume

14

1 reference

1 August 2017

issue

14

1 reference

1 August 2017

page(s)

1969-1975

1 reference

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Serotonin receptors as targets for drugs useful to treat psychosis and cognitive impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

5-HT(2A) inverse-agonists for the treatment of insomnia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Pimavanserin tartrate, a 5-HT(2A) receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Inverse agonism and its therapeutic significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Parkinson's disease: the quintessential neuropsychiatric disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Psychiatric syndromes in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Epidemiology of psychosis in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Benztropine versus clozapine for the treatment of tremor in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Olanzapine treatment for dopaminergic-induced hallucinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Olanzapine in the treatment of dopamimetic-induced psychosis in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

A randomized controlled trial of quetiapine for psychosis in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Quetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Update on typical and atypical antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Clozapine safety, 35 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Serotonin receptors in the human brain--IV. Autoradiographic mapping of serotonin-2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Post-synaptic 5-HT1A and 5-HT2A receptors are increased in Parkinson's disease neocortex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

PET analysis of the 5-HT2A receptor inverse agonist ACP-103 in human brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Pharmacokinetics, tolerability, and safety of ACP-103 following single or multiple oral dose administration in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of parkinson's disease psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2013.819345

10.1517/14656566.2013.819345

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference